Health Affairs, 25, no. 2 (2006): 429-436 doi: 10.1377/hlthaff.25.2.429 © 2006 by Project HOPE	New Online   How Would Obama, McCain Cover The Uninsured?   Debating Cost Of Uninsured   Try Medicare-For-All   HA Blog Top 10

This Article Full Text (HTML) Reprint (PDF) Online Supplement Submit a response to this article View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Ridley, D. B. Articles by Schulman, K. A. Search for Related Content PubMed PubMed Citation Articles by Ridley, D. B. Articles by Schulman, K. A. Related Collections Business Of Health Consumer Issues Health Reform Legal/Regulatory Issues Pharmaceuticals Quality Of Care Research And Technology Health Spending

Health Tracking

MarketWatch

Spending On Postapproval Drug Safety

Withdrawals of high-profile pharmaceuticals have focused attention on post-approval safety surveillance. There have been no systematic assessments of spending on postapproval safety. We surveyed drug manufacturers regarding safety efforts. Mean spending on postapproval safety per company in 2003 was $56 million (0.3 percent of sales). Assuming a constant safety-to-sales ratio, we estimated that total spending on postapproval safety by the top twenty drug manufacturers was $800 million in 2003. We also examined, using regression analysis, the relationship between the number of safety personnel and the number of initial adverse-event reports. This study offers information for the debate on proposed changes to safety surveillance.

                      What's this?

This article has been cited by other articles:

				S. D. Reed, R. M. Califf, and K. A. Schulman How Changes In Drug-Safety Regulations Affect The Way Drug And Biotech Companies Invest In Innovation Health Aff., September 1, 2006; 25(5): 1309 - 1317. [Abstract] [Full Text] [PDF]

				D. B. Ridley, H. G. Grabowski, and J. L. Moe Developing drugs for developing countries. Health Aff., March 1, 2006; 25(2): 313 - 324. [Abstract] [Full Text] [PDF]

eLetters: